Cardiovascular Complication after Kidney Transplantation

Main Article Content

Ho Sik Shin

Abstract

Patient mortality after kidney transplantation continues to be a major clinical challenge, with approximately 1 in 5 recipients dying within 10 years of engraftment. Cardiovascular disease (CVD) is the most common cause of death after the 1-year posttransplant and it has been estimated that the risk of cardiovascular events is 50-fold higher than in the general population. Because of this, post transplant outcomes are substantially influenced by cardiovascular disease. The presence of both traditional and non-traditional risk factors contributes to this overwhelming burden of cardiovascular disease in patients with chronic kidney disease (CKD).

Keywords:
Cardiovascular complication, kidney transplantation, cardiovascular disease, chronic kidney disease.

Article Details

How to Cite
Sik Shin, H. (2019). Cardiovascular Complication after Kidney Transplantation. Journal of Advances in Medicine and Medical Research, 30(10), 1-10. https://doi.org/10.9734/jammr/2019/v30i1030241
Section
Review Article

References

Matas AJ, et al, OPTN/SRTR 2011 Annual Data Report: kidney. Am J Transplant, 2013;13(Suppl 1):11-46.

Opelz G, Dohler B. Association of HLA mismatch with death with a functioning graft after kidney transplantation: A collaborative transplant study report. Am J Transplant. 2012;12(11):3031-8.

Ojo AO. Cardiovascular complications after renal transplantation and their prevention.Transplantation. 2006;82(5): 603-11.

Tsai HI, et al. Cardiovascular disease risk in patients receiving organ transplantation: a national cohort study. Transpl Int; 2017.

Ribic CM, et al. Study of cardiovascular outcomes in renal transplantation: A prospective, multicenter study to determine the Incidence of cardiovascular events in renal transplant recipients in Ontario, Canada. Can J Kidney Health Dis. 2017;4: 2054358117713729.

Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med. 1988;84(6):985- 92.

Vanrenterghem YF, et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation. 2008;85(2):209-16.

Parajuli S, Clark DF, Djamali A. Is Kidney Transplantation a Better State of CKD? Impact on Diagnosis and management. Adv Chronic Kidney Dis. 2016;23(5):287-294.

Findlay MD, et al. Risk factors and outcome of stroke in renal transplant recipients. Clin Transplant. 2016;30(8): 918-24.

Oliveras A, et al. Stroke in renal transplant recipients: Epidemiology, predictive risk factors and outcome. Clin Transplant. 2003;17(1):1-8.

Ghanta M, Kozicky M, Jim B. Pathophysiologic and treatment strategies for cardiovascular disease in end-stage renal disease and kidney transplantations. Cardiol Rev. 2015;23(3):109-18.

Boerner BP, et al. Diabetes and cardiovascular disease following kidney transplantation. Curr Diabetes Rev. 2011; 7(4):221-34.

Jeon HJ, et al. Time-varying maximal proteinuria correlates with adverse cardiovascular events and graft failure in kidney transplant recipients. Nephrology (Carlton). 2015;20(12):945-51.

Aalten J, et al. Associations between pre-kidney-transplant risk factors and post-transplant cardiovascular events and death. Transpl Int. 2008;21(10):985-91.

Go AS, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13):1296-305.

Lentine KL, et al. Cardiovascular risk assessment among potential kidney transplant candidates: Approaches and controversies. Am J Kidney Dis. 2010; 55(1):152-67.

Rao PS, Schaubel DE, Saran R. Impact of graft failure on patient survival on dialysis: a comparison of transplant-naive and post-graft failure mortality rates. Nephrol Dial Transplant. 2005;20(2):387-91.

Fellstrom B, et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant. 2005;5(8):1986-91.

Santos RD. Coronary artery calcification progression and cardiovascular events in renal transplant recipients, bad inheritance from previous kidney disease: commentary on the study of Roe et al. Atherosclerosis. 2010;212(2):390-1.

Bangalore S, et al. Body-weight fluctuations and outcomes in coronary disease. N Engl J Med. 2017;376(14): 1332-1340.

Mangray M, Vella JP. Hypertension after kidney transplant. Am J Kidney Dis. 2011; 57(2):331-41.

Kasiske BL, et al. Hypertension after kidney transplantation. Am J Kidney Dis. 2004;43(6):1071-81.

Cosio FG, et al. Racial differences in renal allograft survival: the role of systemic hypertension. Kidney Int. 1995;47(4):1136-41.

Elzinga LW, et al. The role of renal sympathetic nerves in experimental chronic cyclosporine nephropathy. Transplantation. 2000;69(10):2149-53.

Sander M, et al. Sympathetic neural mechanisms of cyclosporine-induced hypertension. Am J Hypertens. 1996; 9(11):121S-138S.

Curtis JJ, et al. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med. 1988;85(2):134-8.

Watschinger B, Sayegh MH. Endothelin in organ transplantation. Am J Kidney Dis. 1996;27(1):151-61.

Vaziri ND, et al. Depressed renal and vascular nitric oxide synthase expression in cyclosporine-induced hypertension. Kidney Int. 1998;54(2):482-91.

Esteva-Font C, et al. Ciclosporin-induced hypertension is associated with increased sodium transporter of the loop of Henle (NKCC2). Nephrol Dial Transplant. 2007; 22(10):2810-6.

Chiasson VL, et al. Regulatory T-Cell Augmentation or Interleukin-17 Inhibition Prevents Calcineurin Inhibitor-Induced Hypertension in Mice. Hypertension. 2017; 70(1):183-191.

Hricik DE, et al. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation. 1992;54(5):868-71.

Srinivas TR, Meier-Kriesche HU. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol. 2008;(3 Suppl 2):S101-16.

Hricik DE, et al. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation. 1991;51(2):374-7.

Hricik DE, et al. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients. Transplantation. 1992;53(6): 1232-5.

Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis. 1991;18(3):353-8.

Luan FL, et al. Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression. Am J Transplant. 2009;9(1):160-8.

Luan FL, Steffick DE, Ojo AO. Steroid-free maintenance immunosuppression in kidney transplantation: Is it time to consider it as a standard therapy? Kidney Int. 2009;76(8):825-30.

Hricik DE, et al. Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation. 2007;83(3):277-81.

Vincenti F, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant. 2008;8(2):307-16.

Annema W, et al. HDL Cholesterol efflux predicts graft failure in renal transplant recipients. J Am Soc Nephrol. 2016; 27(2):595-603.

Jardine AG, et al. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet. 2011; 378(9800):1419-27.

Israni AK, et al. Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study. Am J Transplant. 2010; 10(2):338-53.

Detection, evaluation, and treatment of high blood cholesterol in adults. Rev Panam Salud Publica. 2001;9(5):338-44.

Bostom AD, et al. Prevention of post-transplant cardiovascular disease-report and recommendations of an ad hoc group. Am J Transplant. 2002;2(6):491-500.

Holdaas H, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet. 2003; 361(9374):2024-31.

Bae J, et al. Statin specific toxicity in organ transplant recipients: Case report and review of the literature. J Nephrol. 2002; 15(3):317-9.

Katznelson S, Kobashigawa JA. Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: Lipid lowering and immunosuppression. Kidney Int Suppl. 1995;52:S112-5.

Kobashigawa JA, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995; 333(10):621-7.

Keddis MT, et al. Enhanced posttransplant management of patients with diabetes improves patient outcomes. Kidney Int. 2014;86(3):610-8.

Gregg EW, et al. Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: Findings from the National Health Interview Survey. Diabetes Care. 2012;35(6):1252-7.

Thomas RJ, et al. Trends in the mortality burden associated with diabetes mellitus: A population-based study in Rochester, Minn, 1970-1994. Arch Intern Med. 2003; 163(4):445-51.

Emerging Risk Factors. C., et al., Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375(9733):2215-22.

Collins AJ, et al. Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis. 2008;51(1 Suppl 1):S1-320.

Cosio FG, et al. Patient survival and cardiovascular risk after kidney transplantation: The challenge of diabetes. Am J Transplant. 2008;8(3):593-9.

Lim EC, Terasaki PI. Outcome of kidney transplantation in different diseases. Clin Transpl. 1990;461-9.

Montori VM, et al. Posttransplantation diabetes: A systematic review of the literature. Diabetes Care. 2002;25(3):583-92.

Porte D Jr. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications. Diabetes Metab Res Rev. 2001;17(3):181-8.

Bloom RD, Crutchlow MF. New-onset diabetes mellitus in the kidney recipient: diagnosis and management strategies. Clin J Am Soc Nephrol. 2008;(3 Suppl 2): S38-48.

Ducloux D, et al. Polycystic kidney disease as a risk factor for post-transplant diabetes mellitus. Nephrol Dial Transplant. 1999; 14(5):1244-6.

Nam JH, et al. Beta-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation. 2001;71(10):1417-23.

Huang JW, et al. Hypomagnesemia and the Risk of New-Onset Diabetes Mellitus after Kidney Transplantation. J Am Soc Nephrol, 2016;27(6):1793-800.

Pirsch JD, et al. New-onset diabetes after transplantation: Results from a double-blind early corticosteroid withdrawal trial. Am J Transplant. 2015; 15(7):1982- 90.

Krishnan N, et al. Kidney transplantation significantly improves patient and graft survival irrespective of BMI: A Cohort Study. Am J Transplant. 2015;15(9): 2378-86.

Naik AS, et al. The Impact of Obesity on Allograft Failure After Kidney Transplantation: A Competing Risks Analysis. Transplantation. 2016;100(9): 1963-9.

Hill CJ, et al. Recipient obesity and outcomes after kidney transplantation: A systematic review and meta-analysis. Nephrol Dial Transplant. 2015;30(8):1403-11.

Freeman CM, et al. Addressing morbid obesity as a barrier to renal transplantation with laparoscopic sleeve gastrectomy. Am J Transplant. 2015;15(5):1360-8.

Garcia-Roca R, et al. Single Center Experience With Robotic Kidney Transplantation for Recipients With BMI of 40 kg/m2 Or Greater: A Comparison With the UNOS Registry. Transplantation. 2017; 101(1):191-196.

Schjelderup P, et al. Anemia is a predictor of graft loss but not cardiovascular events and all-cause mortality in renal transplant recipients: Follow-up data from the alert study. Clin Transplant. 2013;27(6):E636-43.

Fried LF, et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol. 2009;4(2):361-8.

Vanrenterghem Y, et al. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant. 2003;3(7):835-45.

Van Biesen W, et al. Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation. Transplantation. 2005;79(3):367-8.